公开(公告)号：US20250042881A1

公开(公告)日：2025-02-06

申请号：US18704588

申请日：2022-10-25

Applicant: Idorsia Pharmaceuticals Ltd

Inventor： Oliver ALLEMANN ,  Eva CAROFF ,  Francis HUBLER ,  Emmanuel MEYER

IPC: C07D405/14 ,  A61K31/4439 ,  A61K31/4545 ,  C07D401/14

Abstract: The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.

公开(公告)号：US12187756B2

公开(公告)日：2025-01-07

申请号：US17296194

申请日：2019-11-22

Applicant: IDORSIA PHARMACEUTICALS LTD

Inventor： Madhu Emmadi ,  Marilda P. Lisboa ,  Daniel Knopp ,  Bopanna Monnanda ,  Arne Von Bonin ,  Claney Lebev Pereira

IPC: C07H17/04 ,  A61K47/64

Abstract: The present invention relates to a synthetic saccharide of general formulate (I) that is related to Clostridium difficile PS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Clostridium difficile. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Clostridium difficile bacteria.

公开(公告)号：US20240208992A1

公开(公告)日：2024-06-27

申请号：US18550883

申请日：2021-07-12

Applicant: Idorsia Pharmaceuticals Ltd

Inventor： Martin BOLLI ,  Christine BROTSCHI ,  Malgorzata COMMANDEUR ,  John GATFIELD ,  Thierry KIMMERLIN ,  Hervé SIENDT ,  Jasper SPRINGER ,  Clemens WAGNER ,  Anita WEGERT ,  Jodi T. WILLIAMS

IPC: C07D498/04 ,  A61K31/4745

CPC classification number: C07D498/04 ,  A61K31/4745

Abstract: The present invention relates to macrocyclic compounds of Formula (I)






wherein Ar1, Ar2, R1, R2, R3, R4, and X are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as modulators of CFTR.

公开(公告)号：US20240109930A1

公开(公告)日：2024-04-04

申请号：US18548833

申请日：2022-03-02

Applicant: Idorsia Pharmaceuticals Ltd

Inventor： Martin BOLLI ,  John GATFIELD ,  Corinna GRISOSTOMI ,  Lubos REMEN ,  Christoph SAGER ,  Cornelia ZUMBRUNN

IPC: C07H7/06 ,  A61P37/04

CPC classification number: C07H7/06 ,  A61P37/04

Abstract: The present invention relates to Galectin-3 inhibitors of Formula (I) and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds, and their medical uses.

公开(公告)号：US20230192708A1

公开(公告)日：2023-06-22

申请号：US18084911

申请日：2022-12-20

Applicant: Idorsia Pharmaceuticals Ltd.

Inventor： Sylvie FROIDEVAUX ,  Francis HUBLER ,  Mark MURPHY ,  Dorte RENNEBERG ,  Simon STAMM

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: The present invention relates to derivatives of formula (I)




wherein Ring A, X, Y, Z, RA, R1, R2, R3 and R4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as C5a receptor modulators.

公开(公告)号：US20230165859A1

公开(公告)日：2023-06-01

申请号：US18058873

申请日：2022-11-27

Applicant: Idorsia Pharmaceuticals Ltd

Inventor： Heinz FRETZ ,  Isabelle LYOTHIER ,  Julien POTHIER ,  Sylvia RICHARD-BILDSTEIN ,  Thierry SIFFERLEN

IPC: A61K31/506 ,  A61P35/00 ,  A61K45/06 ,  C07D403/12

CPC classification number: A61K31/506 ,  A61P35/00 ,  A61K45/06 ,  C07D403/12

Abstract: The present invention relates to derivatives of formula (I)




wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.

公开(公告)号：US20230047102A1

公开(公告)日：2023-02-16

申请号：US17786965

申请日：2020-11-02

Applicant: Idorsia Pharmaceuticals Ltd

Inventor： Michael Ambuehl ,  Nasser Benniou ,  Frantz Elbaz ,  Frederic Heyer ,  Ibrahima Sow

IPC: A61K31/4439 ,  A61K47/22 ,  A61K47/32 ,  A61K47/38 ,  A61K47/36 ,  A61K47/02 ,  A61K47/12 ,  A61P25/08

Abstract: The present invention relates to solid pharmaceutical compositions comprising N-[1-(5-cyano-pyridin-2−ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or pharmaceutically acceptable salt thereof. The invention further relates to methods for manufacturing said compositions and their uses for the treatment or prevention of diseases and disorders linked to T-type calcium channels such as epilepsy.

公开(公告)号：US20230045939A1

公开(公告)日：2023-02-16

申请号：US17296194

申请日：2019-11-22

Applicant: IDORSIA PHARMACEUTICALS LTD

Inventor： Madhu EMMADI ,  Marilda P. LISBOA ,  Daniel KNOPP ,  Bopanna MONNANDA ,  Arne VON BONIN ,  Claney Lebev PEREIRA

IPC: C07H17/04 ,  A61K47/64

Abstract: The present invention relates to a synthetic saccharide of general formulate (I) that is related to Clostridium difficile PS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Clostridium difficile. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Clostridium difficile bacteria.

公开(公告)号：US20230002365A1

公开(公告)日：2023-01-05

申请号：US17810545

申请日：2022-07-01

Applicant: Idorsia Pharmaceuticals Ltd

Inventor： Cyrille LESCOP ,  Jasper DINGEMANSE ,  Andreas KRAUSE

IPC: C07D413/04 ,  A61P37/00 ,  A61K31/047 ,  A61K31/4245 ,  A61K31/44

Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.

公开(公告)号：US20220324847A1

公开(公告)日：2022-10-13

申请号：US17634512

申请日：2020-08-14

Applicant: Idorsia Pharmaceuticals Ltd

Inventor： Martin BOLLI ,  John GATFIELD ,  Corinna GRISOSTOMI ,  Lubos REMEN ,  Christoph SAGER ,  Cornelia ZUMBRUNN

IPC: C07D405/04 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D409/14

Abstract: The present invention relates to compounds of Formula (I) wherein Ar1, Ar2, L, n, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.